Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/19/2010US7816396 administering 1 mg to about 10 mg of glycopyrrolate without food
10/19/2010US7816395 Pyrrolidinone anilines as progesterone receptor modulators
10/19/2010US7816394 treating headache or migraine pain by contacting topical surface of individual with transdermal patch formulation consisting of an adhesive, an indole serotonin receptor agonist selected from sumatriptan, eletriptan, rizatriptan and zolmitriptan, and at least one hydrophobic oil
10/19/2010US7816393 phosphodiesterase 4 inhibitors such as 4-Carbamoyl-4-{4-[(furan-2-yl-methylamino]-1,3-dioxo 1,3-dihydro-isoindol-2-yl}-butyric acid for treatment of cancer; immunotherapy
10/19/2010US7816390 Such as N-(3-ethoxyphenyl)-1,4-dihydro-6-ethoxy-7-(3-hydroxypropoxy)-1-methylindeno[1,2-c]pyrazole-3-amine; antitumor agents
10/19/2010US7816389 Organic compounds
10/19/2010US7816388 Complexes with radionuclides; radiotherapy or diagnosis of tumors; e.g. two tetraazacyclododecanetetraacetic acid (DOTA) chelators conjugated to the side of biotin
10/19/2010US7816387 β secretase inhibitor
10/19/2010US7816386 Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumor agents
10/19/2010US7816385 Dicarboxy compounds for use as drugs and receptors for proliferation
10/19/2010US7816384 Method for treating a demyelinating condition
10/19/2010US7816383 administering pirfenidone therapy to patient in need thereof, by administering therapeutically effective amount of pirfenidone, and avoiding co-administration of fluvoxamine, wherein patient is also in need of fluvoxamine therapy; treating idiopathic pulmonary fibrosis; reducing adverse drug interaction
10/19/2010US7816382 Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
10/19/2010US7816380 1-hydroxycycloalkanecarboxamide derivatives
10/19/2010US7816379 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate
10/19/2010US7816378 3-{[(3-amino-3-benzyltetrahydrofuran-2-yl)oxy]methyl}-N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[(methylsulfonyl)(propyl)amino]benzamide, used for preventing the formation of insoluble amyloid proteins
10/19/2010US7816377 such as 1-methyl-piperidin-2-carbonsaure-[1-({1-[2-hydroxy-2-(4-phenethylcarbamoyl-thiazol-2-yl)-ethyl]-2-methyl-propyl}-methylcarbamoyl)-2-methyl-butyl]-amide, used for the treatement of adenocarcinoma
10/19/2010US7816376 Use as excitatory amino acid antagonists for combating neurodegenerative and cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, or psychoses; for example, 3-[4-(3,4-methylenedioxybenzyl)piperidino]-N-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propionamide
10/19/2010US7816375 Ligands for monoamine receptors and transporters, and methods of use thereof
10/19/2010US7816374 Administering to respiratory system an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof; chronic obstructive pulmonary disease
10/19/2010US7816372 (R)-6-(2-(2,2,2-Trifluoroethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone; partial agonist, agonist or antagonist of androgen receptor; cachexia and wasting diseases; male-pattern baldness; benign prostatic hyperplasia; hirsutism; acne
10/19/2010US7816371 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
10/19/2010US7816370 Nervous system connecting diseases such as autism
10/19/2010US7816369 Mediators of hedgehog signaling pathways, compositions and uses related thereto
10/19/2010US7816368 1,6-dimethyl-3-(pyridin-4-yl)-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one, used as anticarcinogenic or antitumor agents
10/19/2010US7816367 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
10/19/2010US7816366 treating or preventing dermatoses associated with administration of a 5-fluorouracil or a prodrug thereof in a mammal by topically administering to the mammal a therapeutically or prophylactically effective amount of uracil and a pharmaceutically acceptable carrier
10/19/2010US7816365 Amine derivatives
10/19/2010US7816364 treating osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, using GPR119 agonist in combination with dipeptidyl peptidase IV inhibitor
10/19/2010US7816363 Inhibitors of histone deacetylase
10/19/2010US7816362 piperazine derivatives such as (R)-4-cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)piperazine-1-yl]-propyl}-N-pyridin-2-yl-benzamide, useful as serotonin receptor antagonists, used for the treatment of nervous system disorders, Parkinson's disease, Tourette's syndrome, headache and autism
10/19/2010US7816361 such as 4-(5-Oxo-3-pyrazin-2-yl-2,5-dihydro-pyrazol-1-yl)-N-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-benzamide, used as immunomodulators for the treatment of rheumatoid arthritis, psoriasis, multiple sclerosis and diabetes
10/19/2010US7816360 MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
10/19/2010US7816359 such as (4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide), used as antitumor agents
10/19/2010US7816358 Pharmaceutical formulations comprising N,N′-disubstituted piperazine compounds
10/19/2010US7816357 Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one
10/19/2010US7816356 neurodegenerative diseases, attention deficit disorder, addictive disorders, cognitive enhancers, obesity, Tourette's syndrome, or ulcerative colitis, non-opioid analgesics; compositions of fused ring amines such as benzo(3,4)cyclobuta(1,2-c)pyrrolidine
10/19/2010US7816355 Processes for the preparation of rivaroxaban and intermediates thereof
10/19/2010US7816354 4'-(2-Oxo-5-(R)-phenyl-oxazolidin-3-ylmethyl) biphenyl-3-carboxylic acid (2-dimethylamino-ethyl)-amide, usedd for the treatment or prevention of neurological and psychiatric disorders
10/19/2010US7816353 P70S6 kinase modulators and method of use
10/19/2010US7816352 Apoptosis inhibitors
10/19/2010US7816351 Prevent proliferation of hepatitis C virus; low toxicity
10/19/2010US7816350 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout
10/19/2010US7816349 (R)-3-{3,5-Dichloro-4'-[4-(2-fluoro-ethyl)-piperazine-1-carbonyl]-biphenyl-4-ylmethyl}-1-(4,4-difluoro-cyclohexyl)-pyrrolidin-2-one, used for the treatment of diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome and cognitive disorders
10/19/2010US7816348 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons
10/19/2010US7816347 dual acting compound which acts as a neutral endopeptidase-inhibitor and as an inhibitor of the endogenous endothelin producing system and is selected from daglutril and at least one HMG CoA reductase inhibitor selected from atorvastatin, pravastatin, simvastatin
10/19/2010US7816346 Benzoquinone imine-containing ansamycins and its acylation or alkylation derivatives; cellular proliferation, hyperproliferation; increase the bioavailability and reduce the toxicity associated with the natural product
10/19/2010US7816344 oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics
10/19/2010US7816342 Anti-obesity compositions
10/19/2010US7816341 Edible products, soft and hard capsules
10/19/2010US7816340 Oral immunostimulation of fish from (1-4) linked β-D-mannuronic acid
10/19/2010US7816339 Treatments for Flaviviridae virus infection
10/19/2010US7816338 Compositions and methods for inhibiting car gene expression by RNA interference
10/19/2010US7816337 Drug delivery; to decrease cellular toxicity and improve efficacy
10/19/2010US7816336 Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
10/19/2010US7816335 Therapeutic compounds and methods
10/19/2010US7816334 Nucleic acid construct and nucleic acid expression vectors directing expression of a fusion protein consisting of a disease peptide antigen and a first domain of FrC of tetanus toxin; vaccines
10/19/2010US7816333 nucleosides such as 3',5'-di-O-Benzyl-2'-O,4'-C-ethylene-4-N-benzoylcytidine for treatment of pain, psoriasis, inflammatory disorders, infectious skin disease, skin cancer, Lyme disease, influenza virus, cytomegalovirus, herpes virus, herpes simplex virus, papilloma virus, Epstein Barr virus or HIV
10/19/2010US7816331 Substituted indazole-O-glucosides
10/19/2010US7816330 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
10/19/2010US7816329 inulin sulphate for treatment or prophylaxis of arthritis, osteoarthritis
10/19/2010US7816328 such as 3-(4-Ethylbenzyl)-5-( beta -D-glucopyranosyl)-1H-indole, used for for treating diabetes, Syndrome X, or associated symptoms selected from obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke and cardiovascula disorders
10/19/2010US7816327 Topical administration for therapy of exposure to urushiol; irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin
10/19/2010US7816325 secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV
10/19/2010US7816319 Methods and products for manipulating uncoupling protein expression
10/19/2010US7816318 emulsified nasal spray comprising macrocyclic permeation enhancer, liquid carrier comprising water, hydrocolloid emulsifying agent, and active agent other than insulin such as peptides, peptidomimetics, and proteins
10/19/2010US7816317 Tripeptide prodrug compounds
10/19/2010US7816316 hydrogel of hyaluronic acid derivative chemically crosslinked in solution in presence of pharmacologically active protein or peptide dissolved therein via dithiothreitol
10/19/2010US7816075 treating a human afflicted with condition characterized by elevated serum triglyceride or very low density lipoprotein (VLDL), comprising the step of administering an inhibitor of human delta-9 stearoyl-CoA desaturase (SCD1) activity; coronary artery disease, Type II diabetes, obesity
10/19/2010US7815947 Nutritional composition for controlling blood sugar level
10/19/2010US7815943 Blood flow enhancer and inflamation reducer, anticholesterol agents and oxidation reduction
10/19/2010US7815942 selective irreversible inhibitor of the B-form of the enzyme monoamine oxidase used, for example, for the treatment of Parkinson's disease; R(+)-N-propargyl-1-aminoindan salts, in particular tartrate, esylate, mesylate, or sulfate salts
10/19/2010US7815940 Gastric acid secretion inhibiting composition
10/19/2010US7815938 Film coating
10/19/2010US7815937 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant
10/19/2010US7815936 Using as carriers of pharmaceutical active constituents and/or auxiliary substances
10/19/2010US7815933 Pre-concentrate emulsion of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat, for oral administration; forming an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability; treating pain and inflammation
10/19/2010US7815932 drug layer, support layer insoluble in water comprising ethyl cellulose and hydroxypropyl methylcellulose, backing on support layer, wherein drug layer consists of fentanyl or salt as active ingredient, methyl vinyl ether-maleic anhydride copolymer as adhesive, hydroxypropylcellulose; easily removed
10/19/2010US7815929 container for suppositories comprises a base having a substantially planar surface with a plurality of surface openings; suppository mixture is spread across surface such that mixture falls through openings dispersed across surface and into hollow members
10/19/2010US7815927 biocompatible time-release coatings comprised of acrylate and vinyl monomers containing drugs, on the surfaces of implantable medical equipment
10/19/2010US7815922 Articles having bioactive surfaces and solvent-free methods of preparation thereof
10/19/2010US7815921 Using patient's leukocyte concentration after incubation with colony stimulation factor as evaluative tool in predicting susceptibility to infection, bone marrow and autoimmune diseases after chemotherapeutic treatments
10/19/2010US7815909 human tumor necrosis factor alpha (TNF) inhibitors; for rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis
10/19/2010US7815898 Continuous slow release of a oral drug containing phosphorus binder such as polyallylamine HCL, polyallylamine carbonate, lanthanum carbonate, Al/OH/3, magnesium acetate, MgCO3, CaCO3, calcium acetate, calcium citrate, calcium alginate, styrene-divinylbenzene copolymer, chitosan for hyperphosphatemia
10/19/2010US7814933 Apparatus and method for stabilizing concentration of aerosol
10/19/2010US7814810 Shifter with actuator incorporating shape memory alloy
10/19/2010CA2710014A1 Pirfenidone therapy and inducers of cytochrome p450
10/19/2010CA2621569C Solid salt forms of a pyrrole substituted 2-indolinone
10/19/2010CA2614479C Derivatives of seleno-amino acids
10/19/2010CA2585266C Ophthalmic compositions and methods of using the same
10/19/2010CA2565513C Pharmaceutical compositions comprising zd6474
10/19/2010CA2525245C Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
10/19/2010CA2518745C S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt
10/19/2010CA2478674C Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
10/19/2010CA2474634C Stable pharmaceutical composition useful for treating gastrointestinal disorders
10/19/2010CA2469346C Substituted 2-pyrrolidin-2-yl-1h-indole derivatives for treatment of migraine
10/19/2010CA2468314C The use of water-soluble lamarin in the treatment of cancer
10/19/2010CA2465471C Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
10/19/2010CA2464491C Conditioning solution for contact lenses
10/19/2010CA2464367C Bicyclic compounds
1 ... 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 ... 7860